US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

SIMPLIFY PROPEL OPPORTUNITIES ETF

19.21

-0.0695-0.36%

Post-market: 19.210.00000.00%17:29 EDT

Volume:4K

Turnover:86.39K

Market Cap:82.41M

PE:- -

High:19.40

Open:19.13

Low:19.11

Close:19.28

52wk High:21.31

52wk Low:14.90

Shares:4.29M

Float Shares:4.29M

Volume Ratio:1.58

T/O Rate:0.10%

Dividend:2.72

Dividend Rate:14.16%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Structure weakness ‘disconnected’ from underlying data, says Jefferies

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

BofA Securities Boosts Targets on Chinese CXO Players as Strong Biotech Funding Fuels R&D

Bank of America Securities Raises Targets for Chinese CXO Firms on Strong Biotech Funding

iX Biopharma Warrants See Strong Insider Take-Up, Funding U.S. Expansion

Press Release: SOUTHWEST AIRLINES ANNOUNCES SABRINA CALLAHAN AS CHIEF DIGITAL AND MARKETING OFFICER AND NANDIKA SURI AS VICE PRESIDENT OF RAPID REWARDS

Why Milestone Pharma Stock Is Taking A Dive Today

Benzinga Earnings

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/SURI/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SURI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SURI\",,,,,undefined,":{"symbol":"SURI","market":"US","secType":"STK","nameCN":"SIMPLIFY PROPEL OPPORTUNITIES ETF","latestPrice":19.21,"timestamp":1789156800000,"preClose":19.2795,"halted":0,"volume":4495,"hourTrading":{"tag":"盘后","latestPrice":19.21,"preClose":19.21,"latestTime":"17:29 EDT","volume":20,"amount":385.74,"timestamp":1789162150977,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0036048652714021578,"floatShares":4290001,"shares":4290001,"eps":0,"marketStatus":"Market Closed","change":-0.0695,"latestTime":"09-11 16:00:00 EDT","open":19.13,"high":19.3999,"low":19.11,"amount":86386,"amplitude":0.015037,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":19.2795,"sharesOutstanding":4520001,"nav":19.2283,"aum":82860474.1,"dividendRate":0.141619,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":19.21,"preClose":19.21,"latestTime":"17:29 EDT","volume":20,"amount":385.74,"timestamp":1789162150977,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.584085},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SURI\",,,,,undefined,":{"symbol":"SURI","floatShares":4290001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.584085,"shares":4290001,"dividePrice":2.7205,"high":19.3999,"amplitude":0.015037,"preClose":19.2795,"low":19.11,"week52Low":14.9001,"pbRate":"--","week52High":21.31,"institutionHeld":0,"latestPrice":19.21,"eps":0,"divideRate":0.141619,"volume":4495,"delay":0,"ttmEps":0,"open":19.13,"prevYearClose":16.675,"prevWeekClose":20.3953,"prevMonthClose":20.1,"prevQuarterClose":17.895,"fiveDayClose":20.3,"twentyDayClose":18.819,"sixtyDayClose":17.2999},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SURI\",params:#limit:5,,,undefined,":[{"date":"2026-06-25","symbol":"SURI","amount":0.68,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-25","defaultRemindTime":1782394200000,"name":"SIMPLIFY PROPEL OPPORTUNITIES ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-30","payableDate":"2026-06-25","currency":"USD","dateTimestamp":1782360000000,"payDate":"2026-06-30"},{"date":"2026-03-26","symbol":"SURI","amount":0.68,"announcedDate":"2026-03-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-26","defaultRemindTime":1774531800000,"name":"SIMPLIFY PROPEL OPPORTUNITIES ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-31","payableDate":"2026-03-26","currency":"USD","dateTimestamp":1774497600000,"payDate":"2026-03-31"},{"date":"2025-09-25","symbol":"SURI","amount":0.68,"announcedDate":"2025-09-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-25","defaultRemindTime":1758807000000,"name":"SIMPLIFY PROPEL OPPORTUNITIES ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-25","currency":"USD","dateTimestamp":1758772800000,"payDate":"2025-09-30"},{"date":"2025-06-25","symbol":"SURI","amount":0.68,"announcedDate":"2025-06-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-25","defaultRemindTime":1750858200000,"name":"SIMPLIFY PROPEL OPPORTUNITIES ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-30","payableDate":"2025-06-25","currency":"USD","dateTimestamp":1750824000000,"payDate":"2025-06-30"},{"date":"2025-03-26","symbol":"SURI","amount":0.68,"announcedDate":"2025-03-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-26","defaultRemindTime":1742995800000,"name":"SIMPLIFY PROPEL OPPORTUNITIES ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-31","payableDate":"2025-03-26","currency":"USD","dateTimestamp":1742961600000,"payDate":"2025-03-31"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SURI\",market:\"US\",,,undefined,":[{"executeDate":"2023-03-27","recordDate":"2023-03-28","paymentDate":"2023-03-31","value":1,"currency":"USD"},{"executeDate":"2023-06-27","recordDate":"2023-06-28","paymentDate":"2023-07-03","value":0.68,"currency":"USD"},{"executeDate":"2023-09-27","recordDate":"2023-09-28","paymentDate":"2023-09-29","value":0.68,"currency":"USD"},{"executeDate":"2023-12-26","recordDate":"2023-12-27","paymentDate":"2023-12-29","value":0.68,"currency":"USD"},{"executeDate":"2024-03-25","recordDate":"2024-03-26","paymentDate":"2024-03-28","value":0.68,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SURI\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SURI\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666377632","title":"Structure weakness ‘disconnected’ from underlying data, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377632?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897615,"startTime":"0","endTime":"0","summary":"After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies see...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","XPH","BME","IDNA","MEDX","WDNA","PJP","BBP","GNOM","FHLC","IBBJ","PBPH","BIB","JDOC","CURE","TBXU","PINK","IEIH","FTXH","MEDI","CANC","LFSC","HYLG","PTH","AZNH","CNCR","GNMX","GPCR","GSKH","IBBQ","PSCH","FXH","APXH","MNTL","MRNY","BBH","PSIL","LLYX","MDTX","NVIB","GDOC","JHMH","HRTS","PBE","RSPH","FBT","SBIO","SYNB","SURI","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665637847","title":"Structure Therapeutics reports ACCG-2671, aleniglipron trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665637847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665637847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:36","pubTimestamp":1788871007,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HRTS","FHLC","BME","FTXH","PJP","BIB","TBXU","PSCH","GSKH","CANC","AZNH","IBB","GNOM","NVIB","IBBQ","WDNA","FXH","PBE","CNCR","PBPH","PTH","LENZ","APXH","SBIO","LLYX","BBH","IDNA","CURE","GPCR","PINK","SURI","LFSC","JHMH","MEDX","IBBJ","XPH","SYNB","PSIL","MRNY","FBT","MDTX","MEDI","MNTL","JDOC","IBRN","HYLG","GNMX","BBP","RSPH","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155684243","title":"BofA Securities Boosts Targets on Chinese CXO Players as Strong Biotech Funding Fuels R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=1155684243","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155684243?lang=en_us&edition=fundamental","pubTime":"2026-08-13 12:50","pubTimestamp":1786596641,"startTime":"0","endTime":"0","summary":"BofA Securities has released a report indicating that the Chinese CXO sector is poised to benefit from robust biotech venture capital funding. The bank notes that strong financing in the first half...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSCH","LU0320764599.SGD","BK1583","APXH","IDNA","FHLC","BK1141","IE00B5MMRT66.SGD","LU0348767384.USD","LU1719994722.HKD","LU1997244956.HKD","XBIX","LU1046422090.SGD","LU1969619763.USD","PSIL","SURI","LU2125910500.SGD","LU2242644610.SGD","LU2488822045.USD","LU0052750758.USD","LU1997245177.USD","WX","BK1576","BK0216","BMED","CXO","IE00B543WZ88.USD","MEDI","LU0456842615.SGD","LU0708995583.HKD","603259","LU0611395673.USD","LU1251922891.USD","LU2045819591.USD","161027","LU0700851271.USD","LU2328871848.SGD","LU0348766576.USD","IBRN","LFSC","LU1934453819.USD","LU1979443071.USD","IE00BPRC5H50.USD","LU1997245094.SGD","LU2495084118.USD","LU1808992512.USD","LU1303224171.USD","BBC","LU1770034418.SGD","02359","SMCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111112440","title":"Bank of America Securities Raises Targets for Chinese CXO Firms on Strong Biotech Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=1111112440","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111112440?lang=en_us&edition=fundamental","pubTime":"2026-08-13 10:35","pubTimestamp":1786588544,"startTime":"0","endTime":"0","summary":"A report from Bank of America Securities indicates that Chinese CRO/CDMO companies are poised to benefit from robust first-half funding in the global and Chinese biotech sectors, along with active...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0307460666.USD","LU0029874061.USD","LU3063872942.SGD","PSIL","IE00B5MMRT66.SGD","LU1046422090.SGD","LU1242518857.USD","BK1521","LU2495084118.USD","LU0516422366.SGD","161027","LU1969619763.USD","LU0051755006.USD","LU2328871848.SGD","BK1583","LU0823426480.USD","LU0588546209.SGD","WX","LU0181495838.USD","BK1576","LU1720050803.USD","LU0819121731.USD","LU1303224171.USD","LU1794554557.SGD","LU1251922891.USD","LU0348767384.USD","LU0708995583.HKD","LU0516423091.SGD","SURI","LU0039217434.USD","LU0456846285.SGD","APXH","LU0856984785.SGD","LU2045819591.USD","LFSC","IDNA","BBC","BK1589","SG9999002463.SGD","LU0326950275.SGD","02269","LU0823426308.USD","02359","LU1688375341.USD","IE00B0JY6N72.USD","LU0128526141.USD","LU0348766576.USD","IBRN","LU1997244956.HKD","LU0516422952.EUR","LU0417516738.SGD","LU0140636845.USD","LU2125910500.SGD","LU2039709279.SGD","LU2242644610.SGD","LU0516422440.USD","CXO","LU1880383366.USD","LU0359202008.SGD","SG9999002562.SGD","LU1242518931.SGD","IE00B543WZ88.USD","PSCH","LU0359201612.USD","BK1141","LU1808992512.USD","LU1719994722.HKD","LU0348825331.USD","SMCO","LU0572944931.SGD","LU0516423174.USD","XBIX","LU0043850808.USD","LU0052750758.USD","BMED","FHLC","LU0979878070.USD","LU0611395673.USD","LU2488822045.USD","LU0456827905.SGD","LU1997245094.SGD","KURE","03759","LU0417516902.SGD","BK0216","LU0348735423.USD","MEDI","BK1610","LU0320764599.SGD","LU1997245177.USD","LU0327786744.USD","LU1770034418.SGD","LU1934453819.USD","603259","LU0456842615.SGD","LU0700851271.USD","LU1979443071.USD","IE00BPRC5H50.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651468729","title":"iX Biopharma Warrants See Strong Insider Take-Up, Funding U.S. Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2651468729","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651468729?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:08","pubTimestamp":1784117284,"startTime":"0","endTime":"0","summary":"The latest update is out from iX Biopharma Ltd. ( ($SG:42C) ). Singapore-based iX Biopharma Ltd. operates in the biopharmaceutical industry, focusi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ix-biopharma-warrants-see-strong-insider-take-up-funding-u-s-expansion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ix-biopharma-warrants-see-strong-insider-take-up-funding-u-s-expansion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RSPH","BK4209","GSKH","PPH","SURI","SG","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627428666","title":"Press Release: SOUTHWEST AIRLINES ANNOUNCES SABRINA CALLAHAN AS CHIEF DIGITAL AND MARKETING OFFICER AND NANDIKA SURI AS VICE PRESIDENT OF RAPID REWARDS","url":"https://stock-news.laohu8.com/highlight/detail?id=2627428666","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627428666?lang=en_us&edition=fundamental","pubTime":"2026-04-15 00:00","pubTimestamp":1776182400,"startTime":"0","endTime":"0","summary":"New Leaders support evolving Customer Experience and maintaining Southwest's legendary Hospitality. DALLAS, April 14, 2026 /PRNewswire/ -- Southwest Airlines Co.  today announced that Sabrina Callahan recently joined the airline as its first Chief Digital and Marketing Officer, bringing extensive experience driving growth and transformation across digital and eCommerce, brand, social, and marketing. Additionally, Nandika Suri joins as Vice President of Rapid Rewards to lead the Company's award-winning loyalty program.Sabrina and Nandika are joining a Southwest Airlines leadership team that is focused on evolving the Customer Experience and investing in the digital journey while further strengthening the Southwest brand that people know and love.About Sabrina Callahan, Chief Digital and Marketing Officer. In her role, Sabrina will help shape the strategic path for the Company's marketing and digital strategy, enhancing the relationship between Southwest's Customers and its brand in an a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4008","VICE","BK4585","LUV","BK4232","BK4588","SURI","BK4500","BK4022","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620122730","title":"Why Milestone Pharma Stock Is Taking A Dive Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2620122730","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620122730?lang=en_us&edition=fundamental","pubTime":"2026-03-20 23:40","pubTimestamp":1774021220,"startTime":"0","endTime":"0","summary":"EU decision delay for Milestone Pharmaceuticals etripamil, despite strong U.S. launch progress, solid sales beat and cash runway into 2027.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/03/51382636/why-milestone-pharma-stock-is-taking-a-dive-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIST","BK4217","SMA","BK4007","SURI"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}]}}